Shiliang Liu

6PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 10, 2026
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002).

Baoqing Chen, Shiliang Liu, Yujia Zhu

|Dec 19, 2025
Integrating lymphovascular invasion and ypTNM staging system for esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy and surgery: a multi-institutional analysis.

Shiliang Liu, Yujin Xu, Xufeng Guo

|Dec 18, 2024
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.

Mian Xi, Zhoutian Yang, Li Hu

|Jun 27, 2024
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study.

Ruixi Wang, Shiliang Liu, Baoqing Chen

|Mar 01, 2024
Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab.

Baoqing Chen, Shiliang Liu, Yujia Zhu

|Jun 30, 2021
Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial.

Shiliang Liu, Liling Luo, Lei Zhao

Pageof 1

Frequent Collaborators

6 joint publications

Mian Xi

5 joint publications

Baoqing Chen

4 joint publications

Qiaoqiao Li

3 joint publications

Yujia Zhu